Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cisplatin
100%
Chemotherapy
100%
Advanced Gastric Adenocarcinoma
100%
5-fluorouracil (5-FU)
100%
Epirubicin
100%
Phase II Trial
50%
Stomach Adenocarcinoma
50%
Well Tolerated
50%
Israel
25%
Clinical Trials
25%
Treatment-related Mortality
25%
Disease Progression
25%
Partial Response
25%
In(III)
25%
1-year Mortality
25%
Anemia
25%
Vomiting
25%
Continuous Intravenous Infusion
25%
Survival Rate
25%
Response Rate
25%
% Response
25%
Stage IV Disease
25%
Chemotherapy Regimen
25%
Complete Response
25%
4-cycle
25%
Admission to Hospital
25%
Neutropenia
25%
Hematotoxicity
25%
Median Survival
25%
Conventional Chemotherapy
25%
Disease-free
25%
Febrile Neutropenia
25%
Liver Metastasis
25%
Initial Surgery
25%
Advanced Gastric Cancer
25%
Total number of Cycles
25%
Relative Dose Intensity
25%
Response Evaluation
25%
Toxicity Evaluation
25%
Community Practice
25%
Median Progression-free Survival
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cisplatin
100%
Stomach Adenocarcinoma
100%
Chemotherapy Regimens
100%
Fluorouracil
100%
Epirubicin
100%
Diseases
75%
Adenocarcinoma
50%
Progression Free Survival
25%
Clinical Trial
25%
Phase II Trials
25%
Disease Exacerbation
25%
Survival Rate
25%
Neutropenia
25%
Anemia
25%
Febrile Neutropenia
25%
Liver Metastasis
25%
Abdominal Cancer
25%
Phase III Trials
25%